Pregnant Patient Injury Medications and Pharmacy Lien Considerations

James Wong — Founder & Pharmacist, LienScripts | March 26, 2026 | 7 min read

Pregnancy severely restricts available pain medications after a personal injury, leaving attorneys with cases where limited treatment options themselves document the injury's impact. FDA pregnancy categories, contraindicated medications, and restricted alternatives create a unique pharmaceutical record for demand packages.

Pregnant Patient Injury Medications and Pharmacy Lien Considerations

Pregnant patient injury medication management is defined by severe pharmaceutical restrictions — the majority of standard personal injury medications are contraindicated or carry FDA pregnancy risk warnings that limit the treating physician to a narrow set of safer alternatives. For personal injury attorneys, a pregnant plaintiff's medication record tells a powerful story: the patient is injured, in pain, and unable to access the full range of treatments available to non-pregnant patients because of the pregnancy. The medication restrictions themselves are evidence of the injury's compounded impact.

• NSAIDs (ibuprofen, naproxen, meloxicam) are contraindicated in the third trimester and carry risk warnings throughout pregnancy, eliminating the most common PI anti-inflammatory medications
• Opioids carry FDA pregnancy risk and neonatal withdrawal concerns, limiting pain management to the lowest effective dose for the shortest possible duration
• Muscle relaxants (cyclobenzaprine, tizanidine, methocarbamol) lack adequate pregnancy safety data, restricting or eliminating this entire drug class from the treatment plan
• Acetaminophen is often the only widely accepted analgesic, leaving severe injuries undertreated compared to the same injury in a non-pregnant patient
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report that documents both the medications prescribed and the medications withheld due to pregnancy — creating evidence of restricted treatment that supports higher damages

FDA Pregnancy Risk Categories and Their Evidentiary Value

The FDA historically categorized medications using pregnancy risk categories A, B, C, D, and X (replaced in 2015 by the Pregnancy and Lactation Labeling Rule, though the letter categories remain widely referenced in clinical practice). Understanding these categories is essential for attorneys because they explain why the treating physician was forced into limited treatment options.

According to James Wong, PharmD, founder of LienScripts, "When I review a pregnant PI patient's medication record, what stands out is not what was prescribed — it is what was not prescribed. The treating physician could not use NSAIDs, could not use most muscle relaxants, and could not use standard neuropathic agents. That restriction is itself evidence that the pregnancy compounded the injury's impact on the patient's life."

Key medication restrictions in pregnancy:

• Category X (contraindicated): Misoprostol (used for NSAID gastroprotection), methotrexate, isotretinoin — these cannot be prescribed under any circumstances during pregnancy
• Category D (positive evidence of risk): Benzodiazepines (lorazepam, diazepam), certain anticonvulsants (valproic acid, phenytoin), some opioids in late pregnancy
• Category C (risk cannot be ruled out): Gabapentin, pregabalin, tramadol, most muscle relaxants, most antidepressants
• Category B (no evidence of risk in humans): Acetaminophen, certain antibiotics, some antihistamines

[!KEY] The medications a pregnant PI patient cannot take are as important as the medications she can take. When the demand package documents that the patient's treating physician was unable to prescribe NSAIDs, muscle relaxants, or neuropathic agents due to pregnancy, it establishes that the injury caused undertreatment — a distinct damages category proving the patient endured more suffering than a non-pregnant person with the identical injury.

What Can Be Safely Prescribed

The restricted medication menu for pregnant PI patients includes:

Acetaminophen: The Default — and Often Only — Analgesic

Acetaminophen (Tylenol) is the most widely accepted analgesic during pregnancy. It is the default recommendation for mild to moderate pain across all trimesters. However, acetaminophen has significant limitations:

• No anti-inflammatory properties (unlike NSAIDs)
• Maximum daily dose of 3000-4000 mg limits pain coverage
• Ineffective for moderate-to-severe musculoskeletal pain as a sole agent
• Recent studies have raised concerns about prenatal acetaminophen exposure and developmental outcomes, adding complexity to even this default option

Limited Opioid Use in Severe Cases

When a pregnant patient's injury produces severe pain that acetaminophen alone cannot manage, short-course opioid therapy may be prescribed with extensive documentation of the risk-benefit analysis:

• Oxycodone or hydrocodone — may be used in the lowest effective dose for the shortest duration, particularly in the second trimester when organogenesis is complete but third-trimester neonatal risks are still distant
• Codeine — historically used in pregnancy but carries its own risk profile
• Neonatal abstinence syndrome (NAS) risk — any opioid use in late pregnancy carries risk of neonatal withdrawal, requiring coordination with the patient's OB/GYN and documentation of the prescribing rationale

Topical Agents: The Safety-First Alternative

Topical medications that minimize systemic absorption are often the primary treatment modality for pregnant PI patients:

• Topical lidocaine patches — provide localized pain relief with minimal systemic absorption
• Menthol-based topical preparations — used for muscle pain and spasm
• Capsaicin cream — topical analgesic with no systemic absorption concerns
• Ice and heat — while not pharmaceutical, their prominence in the treatment plan when medications are restricted is itself evidence of limited options

[!TIP] Request the treating physician's office notes documenting the pregnancy-related medication restrictions. Pair these notes with the pharmacy record showing the limited medications actually dispensed. The contrast between what a non-pregnant patient would receive and what the pregnant patient actually received is the foundation of the restricted-treatment damages argument.

Trimester-Specific Medication Considerations

First Trimester (Weeks 1-12): Maximum Restriction

The first trimester — the period of organogenesis — is when medication risks are highest. Virtually all elective medications are avoided. This means a PI patient injured during the first trimester may go weeks with only acetaminophen and topical agents for what could be a significant musculoskeletal injury.

Second Trimester (Weeks 13-26): Slightly Expanded Options

Some medications may be cautiously introduced in the second trimester:

• Short-course opioids with OB/GYN coordination
• Certain antihistamines (diphenhydramine, category B) for sleep disruption
• Physical therapy escalation to compensate for pharmaceutical restrictions

Third Trimester (Weeks 27-40): NSAID Contraindication

NSAIDs are specifically contraindicated in the third trimester due to the risk of premature closure of the ductus arteriosus in the fetus. A patient injured in the third trimester has the most restricted medication options of any PI plaintiff demographic.

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "The trimester at the time of injury directly determines the medication options available. A first-trimester injury produces the longest period of restricted treatment. A third-trimester injury eliminates NSAIDs entirely. Both create documentation of undertreatment that supports higher damages."

Post-Delivery Medication Considerations

After delivery, the medication restrictions shift but do not disappear entirely for breastfeeding mothers:

• Breastfeeding restrictions continue to limit certain medications (benzodiazepines, some opioids, certain antidepressants)
• Delayed treatment initiation — medications that were withheld during pregnancy (NSAIDs, gabapentin, muscle relaxants) may be started post-delivery, and the delay between injury and treatment initiation documents months of undertreatment
• Postpartum recovery combined with injury recovery creates a compound rehabilitation burden

[!KEY] The delayed medication initiation after delivery is powerful evidence. When the pharmacy record shows gabapentin, NSAIDs, or muscle relaxants starting 3-6 months after the injury date — coinciding with delivery or breastfeeding cessation — it documents that the patient endured months of restricted pain management that a non-pregnant plaintiff would not have experienced.

The Pharmacy Lien for Pregnant PI Patients

The LienScripts pharmacy lien covers all pregnancy-safe medications at zero upfront cost and provides pharmacist oversight of pregnancy-specific drug safety. This oversight includes:

• Screening every prescription against current pregnancy safety data
• Coordinating with the treating physician and OB/GYN when medication decisions require joint clinical input
• Documenting pregnancy-related medication restrictions in the MERIT report
• Transitioning the patient to the full medication formulary post-delivery when breastfeeding status permits

The MERIT report for a pregnant PI patient explicitly documents the restricted treatment timeline alongside the medications dispensed, creating a comprehensive record that supports the undertreatment damages argument in the demand package.

Related Resources

• Pain Management After an Accident
• Soft Tissue Injury Medications in PI Cases
• Specialty Medications in Personal Injury
• Pharmacy Lien Enrollment Process
• What Is a MERIT Report?